Truist Securities Reiterates Buy on Merck & Co, Raises Price Target to $142
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Merck & Co (NYSE:MRK) and increased the price target from $139 to $142.
March 28, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a Buy rating on Merck & Co and raised the price target from $139 to $142.
The reiteration of a Buy rating combined with an increased price target by a reputable analyst like Robyn Karnauskas signals a strong vote of confidence in Merck & Co's future performance. This is likely to be viewed positively by the market, potentially leading to a short-term increase in the stock price as investors react to the analyst's upgraded outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100